Enbrel Promotions May Use AUC Data, Erosion Scores, Not Superiority Claims
Executive Summary
Immunex' Enbrel promotions may use data on percentages of patients with no increase in erosion scores and area under the curve data, but may not use the data to make superiority claims to methotrexate, the approval letter for a new indication for Enbrel states.
You may also be interested in...
Centocor Remicade Two-Year X-Ray Progression Data To Be Ready For Cmte.
Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.
Centocor Remicade Two-Year X-Ray Progression Data To Be Ready For Cmte.
Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.
Immunex Plans Enbrel Early RA Consumer Ad Campaign For Summer Launch
Immunex will roll out a new series of direct-to-consumer print ads to support Enbrel for early rheumatoid arthritis following FDA approval of the new indication, expected this summer.